BLOOMFIELD, Conn., February 04, 2015 -
Cigna (NYSE: CI) has reached an agreement with Gilead Sciences, Inc.
(NASDAQ: GILD) to include Harvoni as the only preferred brand
prescription drug treatment for customers with hepatitis C genotype 1,
the most common form of the disease in the United States. Cigna clients
and customers benefit from obtaining breakthrough clinical cure rates
for hepatitis C while significantly lowering the cost of drug treatment.
Improving customers' health at the most competitive pricing benefits
Harvoni is the only Cigna preferred hepatitis C drug treatment for
“Cigna is committed to offering customers and clients the most
affordable solutions that deliver improved health while containing both
drug and total medical costs. We have selected Gilead’s Harvoni as the
preferred drug treatment for hepatitis C genotype 1. Harvoni’s clinical
effectiveness, safety and convenience, coupled with our innovative
customer counseling, will deliver material health and financial outcomes
for our customers and clients,” said Jon Maesner, chief pharmacy officer
for Cigna Pharmacy Management.
Clinical studies have shown that 94% to 99% of individuals with genotype
1 hepatitis C treated with Harvoni achieve a sustained virologic
response (SVR). Customers who have an SVR when tested 12 weeks after the
completion of treatment are considered cured.
“Cigna continues to invest in analyzing real-world SVR outcomes with the
leading hepatitis C treatments across the genotypes as we believe
creating alignment around clinical and financial outcomes drives more
affordable access to essential medications,” added Maesner. The
agreement includes development of an innovative outcomes incentive
alignment based on actual SVR results across Cigna's customer population.
Cigna is continuing to:
Cigna Medicare customers will also now have Harvoni as an additional
formulary choice for treatment.
Offer therapy support management through Cigna Specialty Pharmacy
Services to every customer undergoing hepatitis C treatment.
Conduct real-world outcomes assessments on existing and new hepatitis
C drug treatments, including Harvoni, to further develop outcome-based
Terms of the agreement are not disclosed.
Read complete press release here
Labels: Cigna, Exclusivity Deals